LBBAP: A More Effective Approach to Cardiac Resynchronization Therapy

New data presented on April 14, 2026, suggests that left bundle branch area pacing (LBBaP) is an effective and practical strategy for cardiac resynchronization therapy (CRT), offering a more physiological approach to restoring heart synchrony compared to traditional methods.

The findings were shared during a Late-Breaking Science presentation at the annual congress of the European Heart Rhythm Association (EHRA) 2026 in Paris, France. The presentation detailed the results of the LECART study, which compared the newer LBBaP method against the standard approach of biventricular pacing (BVP).

Comparison of Pacing Strategies

Cardiac resynchronization therapy is utilized for patients with heart failure who remain symptomatic despite guideline-recommended medical therapy and exhibit electrical dyssynchrony. Specifically, the therapy targets patients with reduced left ventricular ejection fraction (LVEF) who show a dyssynchronous ECG pattern known as left bundle branch block.

While biventricular pacing has served as the established standard for CRT, the LECART study highlights significant limitations associated with this approach. Traditional BVP relies on ventricular cell-to-cell conduction and fails to recruit the heart’s own conduction system to correct the left bundle branch block.

CRT with biventricular pacing is a well-established standard approach but up to one-third of patients do not respond

Professor Jean-Benoît le Polain de Waroux, AZ Sint-Jan Hospital, Bruges, Belgium

In contrast, LBBaP acts as a physiological pacing modality. By stimulating the conduction system directly, it aims to restore synchrony more effectively than the cell-to-cell method used in BVP.

Clinical Benefits and Outcomes

The LECART study found that LBBaP is not only effective but also a practical alternative to standard CRT. One of the primary advantages identified was a reduction in device-related complications.

This decrease in complications leads to a direct clinical benefit for the patient: a reduced necessity for repeat operations. The new pacing option may shorten the duration of the initial implant procedures.

Medical research indicates that LBBaP is a viable alternative for treating heart failure patients with reduced LVEF and asynchrony of cardiac electromechanical activity. By recruiting the conduction system, the therapy seeks to improve the overall outcomes of cardiac resynchronization.

Mechanisms and Limitations

The fundamental difference between the two therapies lies in how they trigger the heart’s contractions. BVP-CRT is often hindered by procedural restrictions for optimal pacing and a high nonresponder rate because it does not utilize the natural electrical pathways of the heart.

LBBaP addresses these issues by targeting the left bundle branch area, which allows for a more natural activation of the left ventricle. This approach is designed to overcome the failures associated with the traditional BVP method.

Despite these positive findings, experts emphasize that more evidence is required to fully establish LBBaP as the primary standard. Professor Jean-Benoît le Polain de Waroux noted that there remains a lack of data from head-to-head randomised trials comparing the two modalities.

As LBBaP continues to emerge as a viable alternative, the medical community is focusing on the success rates, challenges, and troubleshooting necessary to optimize this physiological pacing modality for heart failure patients.